STOK

Stoke Therapeutics Inc

STOK, USA

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

https://www.stoketherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
STOK
stock
STOK

Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00 at HC Wainwright MarketBeat

Read more →
STOK
stock
STOK

STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$31.625

Analyst Picks

Strong Buy

7

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

43.61

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

6.16

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.45 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.64 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-286.85 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.17

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 124.32% of the total shares of Stoke Therapeutics Inc

1.

FMR Inc

(13.528%)

since

2025/06/30

2.

BlackRock Inc

(10.8118%)

since

2025/06/30

3.

RTW INVESTMENTS, LLC

(9.3499%)

since

2025/06/30

4.

Baker Bros Advisors LP

(8.4563%)

since

2025/06/30

5.

Redmile Group, LLC

(7.9857%)

since

2025/06/30

6.

Morgan Stanley - Brokerage Accounts

(6.5222%)

since

2025/06/30

7.

Skorpios Trust

(5.9422%)

since

2025/06/30

8.

The Toronto-Dominion Bank

(5.7909%)

since

2025/06/30

9.

Vanguard Group Inc

(5.3766%)

since

2025/06/30

10.

Marshall Wace Asset Management Ltd

(4.1983%)

since

2025/06/30

11.

Siren, L.L.C.

(4.1012%)

since

2025/06/30

12.

Fidelity Select Biotechnology

(2.8575%)

since

2025/07/31

13.

Vanguard Total Stock Mkt Idx Inv

(2.8104%)

since

2025/07/31

14.

State Street Corp

(2.7139%)

since

2025/06/30

15.

Goldman Sachs Group Inc

(2.3749%)

since

2025/06/30

16.

Polar Capital Biotech S Inc

(2.2811%)

since

2025/07/31

17.

Fidelity Select Health Care

(2.1899%)

since

2025/07/31

18.

iShares Russell 2000 ETF

(1.8107%)

since

2025/08/31

19.

Geode Capital Management, LLC

(1.7755%)

since

2025/06/30

20.

Fidelity Stock Selector Small Cap

(1.774%)

since

2025/06/30

21.

Polar Capital Holdings PLC

(1.6126%)

since

2025/06/30

22.

FIAM Small Cap Core CIT Cl B

(1.5895%)

since

2025/06/30

23.

BlackRock Health Sciences Opps Inv A

(1.5643%)

since

2025/07/31

24.

BGF World Healthscience A2

(1.5532%)

since

2025/05/31

25.

Fidelity Series Small Cap Opps

(1.5262%)

since

2025/06/30

26.

MPM Oncology Impact Management LP

(1.4411%)

since

2025/06/30

27.

Fidelity Advisor Biotechnology I

(1.2988%)

since

2025/07/31

28.

Fidelity Advisor Health Care I

(1.2592%)

since

2025/07/31

29.

Dimensional Fund Advisors, Inc.

(1.2298%)

since

2025/06/30

30.

CI Private Wealth LLC

(1.2041%)

since

2025/06/30

31.

SPDR® S&P Biotech ETF

(1.1441%)

since

2025/08/31

32.

Opaleye Management Inc

(1.0258%)

since

2025/06/30

33.

Bank of America Corp

(1.0002%)

since

2025/06/30

34.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7992%)

since

2025/07/31

35.

Fidelity Small Cap Index

(0.7528%)

since

2025/06/30

36.

iShares Russell 2000 Growth ETF

(0.6508%)

since

2025/08/31

37.

BlackRock Health Sciences Term Trust

(0.5641%)

since

2025/06/30

38.

Fidelity Series Small Cap Core

(0.5254%)

since

2025/06/30

39.

Strategic Advisers Fidelity US TtlStk

(0.465%)

since

2025/07/31

40.

iShares Biotechnology ETF

(0.4627%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.65

EPS Estimate

-0.5805

EPS Difference

-0.0695

Surprise Percent

-11.9724%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.